Chlamydia pneumoniae
Chlamydophila pneumoniae
General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.
Overview
An obligate intracellular bacterium spread by respiratory droplets.
Infections
Pharyngitis, sinusitis, bronchitis and atypical pneumonia.
Signs and symptoms
Sore throat and hoarseness followed by a prolonged cough; often mild.
Antibiotic and antimicrobial resistance
Clinically significant resistance to macrolides, tetracyclines or fluoroquinolones is not a recognized routine problem. Beta-lactams are ineffective against this intracellular organism.
Treatment considerations
Doxycycline, a macrolide or a respiratory fluoroquinolone.
Sources
Sources accessed November 2026. Links open external sites that InnovexLab does not control.
Medical disclaimer
This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.
Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.